Log In
Print
BCIQ
Print
Print this Print this
 

TKM-Ebola (TKM-100201) (formerly Ebola SNALP)

  Manage Alerts
Collapse Summary General Information
Company Tekmira Pharmaceuticals Corp.
DescriptionCombination of short interfering RNAs (siRNAs) targeting Zaire Ebola L polymerase, Zaire Ebola membrane-associated protein (VP24) and Zaire Ebola polymerase complex protein (VP35) formulated with Tekmira's lipid nanoparticle (LNP) technology
Molecular Target
Mechanism of Action 
Therapeutic ModalityNucleic acid: Linear RNA: siRNA
Latest Stage of DevelopmentPhase I
Standard IndicationEbola
Indication DetailsTreat Ebola virus infection
Regulatory Designation

U.S. - Fast Track (Treat Ebola virus infection)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today